Trial: Atacand cuts risk of developing diabetes

New clinical data demonstrates that AstraZeneca's Atacand reduced the risk of developing diabetes among heart failure patients. The data, published in Circulation, shows 6 percent of the group receiving Atacand developed diabetes, compared to 7.4 percent of the control group taking a placebo.

"This finding that candesartan may prevent the development of diabetes in some patients could have important future implications for the treatment of certain patient populations, such as those with hypertension, previous myocardial infarction and heart failure, in whom such treatments have already been shown to reduce major vascular events," remarked lead investigator Dr. Salim Yusuf of McMaster University.

- read this article from MarketWatch for more

ALSO: A separate trial has shown that AtraZeneca's Seroquel works to control both the manic and depressive phases of manic depression. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.